Results 21 to 30 of about 398,598 (315)

Drug*placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design

BMC Medical Research Methodology, 2016
Background Conventional randomized placebo-controlled study design assumes the absence of drug*placebo interaction. We hypothesized the presence of such an interaction and that conventionally estimated drug effect might be biased.
Muhammad M. Hammami, Safa Hammami, Reem Al-Swayeh, Eman Al-Gaai, Faduma Abdi Farah, Sophia J. S. De Padua   +5 more
doaj   +1 more source

Placebo and the law of identification

Frontiers in Psychiatry
Thousands of essays and studies have been published on placebo and nocebo. Yet, despite this plethora of information, we are not much closer to a comprehensive understanding of the fundamental mechanism producing placebo and nocebo effects than we were ...
Steve F. Bierman, Andrew Weil, Stephen Dahmer   +2 more
doaj   +1 more source

The Role of Expectation and Beliefs on the Effects of Non-Invasive Brain Stimulation

Brain Sciences, 2021
Non-invasive brain stimulation (NIBS) techniques are used in clinical and cognitive neuroscience to induce a mild magnetic or electric field in the brain to modulate behavior and cortical activation.
Miriam Braga, Diletta Barbiani, Mehran Emadi Andani, Bernardo Villa-Sánchez, Michele Tinazzi, Mirta Fiorio   +5 more
doaj   +1 more source

Change in Cognition Following Ischaemic Stroke

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cognitive decline can occur following ischaemic stroke. How cognition changes over time and associations with cognitive change are poorly understood. This study aimed to explore these issues over 2 years following ischaemic stroke.
Wenci Yan, Terence Quinn, Alex McConnachie, Niall Broomfield, Yun Wong, David Dickie, Kirsten Forbes, Matthew Walters, Jesse Dawson   +8 more
wiley   +1 more source

What Is the Role of the Placebo Effect for Pain Relief in Neurorehabilitation? Clinical Implications From the Italian Consensus Conference on Pain in Neurorehabilitation

Frontiers in Neurology, 2018
BackgroundIt is increasingly acknowledged that the outcomes of medical treatments are influenced by the context of the clinical encounter through the mechanisms of the placebo effect. The phenomenon of placebo analgesia might be exploited to maximize the
Gianluca Castelnuovo, Gianluca Castelnuovo, Emanuele Maria Giusti, Emanuele Maria Giusti, Gian Mauro Manzoni, Gian Mauro Manzoni, Donatella Saviola, Samantha Gabrielli, Marco Lacerenza, Giada Pietrabissa, Giada Pietrabissa, Roberto Cattivelli, Roberto Cattivelli, Chiara Anna Maria Spatola, Chiara Anna Maria Spatola, Alessandro Rossi, Giorgia Varallo, Margherita Novelli, Valentina Villa, Francesca Luzzati, Andrea Cottini, Carlo Lai, Eleonora Volpato, Eleonora Volpato, Cesare Cavalera, Francesco Pagnini, Francesco Pagnini, Valentina Tesio, Lorys Castelli, Mario Tavola, Riccardo Torta, Marco Arreghini, Loredana Zanini, Amelia Brunani, Ionathan Seitanidis, Giuseppe Ventura, Paolo Capodaglio, Guido Edoardo D’Aniello, Guido Edoardo D’Aniello, Federica Scarpina, Andrea Brioschi, Matteo Bigoni, Lorenzo Priano, Lorenzo Priano, Alessandro Mauro, Alessandro Mauro, Giuseppe Riva, Giuseppe Riva, Daniele Di Lernia, Claudia Repetto, Camillo Regalia, Enrico Molinari, Enrico Molinari, Paolo Notaro, Stefano Paolucci, Giorgio Sandrini, Giorgio Sandrini, Susan Simpson, Susan Simpson, Brenda Kay Wiederhold, Santino Gaudio, Jeffrey B. Jackson, Stefano Tamburin, Fabrizio Benedetti   +63 more
doaj   +1 more source

Study of the placebo effect with a placebo test

Comprehensive Psychiatry, 1968
Summary This paper briefly reviewed several methodological problems in studies of the placebo effect. The importance of finding appropriate measures of placebo effect was emphasized. This led to an attempt to develop a more valid and reliable test of placebo reactivity.
A K, Shapiro, H, Wilensky, E L, Struening   +2 more
openaire   +2 more sources

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which ...
Regina Berkovich, Tilman Schneider‐Hohendorf, Eric Baetscher, Evan L. Riddle, Marie Deffner, Emily Katsnelson, Janine Ferrant‐Orgettas, Julie Czerkowicz, John Anderson, Susan E. Goelz, Nicholas Schwab   +10 more
wiley   +1 more source

Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating Scale

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The placebo response in clinical trials in ataxias complicates outcome interpretation and potentially obscures genuine treatment effects. We analyzed placebo group data from past trials in Friedreich Ataxia and observed notable responses in appendicular items, in contrast to minimal changes in axial function, as measured by respective ...
Christian Rummey, Jennifer M. Farmer, David R. Lynch   +2 more
wiley   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Should we reconsider the routine use of placebo controls in clinical research?

Trials, 2012
Background Modern clinical-research practice favors placebo controls over usual-care controls whenever a credible placebo exists. An unrecognized consequence of this preference is that clinicians are more limited in their ability to provide the benefits ...
Avins Andrew L, Cherkin Daniel C, Sherman Karen J, Goldberg Harley, Pressman Alice   +4 more
doaj   +1 more source